<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1467237886;
mso-list-template-ids:-1408354444;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1778869300;
mso-list-template-ids:-612435658;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1794981180;
mso-list-template-ids:-652592534;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-029.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7JIckrxQ$" target="_blank"><span style="color:#0563C1">The Intersection of Sex and Gender Influences on Health and Disease
(R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research
applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 <a href="https://urldefense.com/v3/__https://orwh.od.nih.gov/sites/orwh/files/docs/ORWH_Strategic_Plan_2019_02_21_19_V2_508C.pdf__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH71PTq3m8$"><span style="color:#0563C1">Trans-NIH
Strategic Plan for Women's Health Research</span></a> "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women’s Health (ORWH) and
the scientific partnering Institutes and Centers across NIH.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 25, 2019; November 25, 2020; and November 26, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for November 2019 deadline: November 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.mda.org/research/funding-opportunities__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7x4AWVUQ$" target="_blank"><span style="color:#0563C1">Muscular Dystrophy Association: Discovery Research and Translational Research</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Discovery Research Grants</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Discovery research includes the search for understanding the causes of disease, unraveling pathways involved in disease, identifying novel drug targets, and testing new strategies to treat
disease. The goal for discovery research is to form a solid foundation that informs and accelerates all subsequent drug development. Since each rare disease poses unique challenges to therapy development, discovery research may include various types of studies
related to the unmet needs of each disorder including the creation of improved disease models, biomarker discovery, and the identification of the genetic causes of disease, among others. Discovery Research Grants are awarded to independent, established investigators
to accelerate progress toward understanding and treating neuromuscular disease and total $100,000 per year for one to three years. In a very limited number of cases, awards will exceed $100,000 per year, but pre-approval is required before letter of intent
submission.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Translational Research Grants</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">MDA’s translational research program represents an innovative way to fund research that’s designed to move new drug targets into the clinic as rapidly and efficiently as possible. The
program was developed in response to the increasing number of promising therapeutic avenues for neuromuscular diseases that have developed from MDA's discovery research program.
<a href="https://urldefense.com/v3/__https://www.mda.org/research/mda-venture-philanthropy__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Oflwg1M$"><span style="color:#0563C1">MDA Venture Philanthropy</span></a> is the Muscular Dystrophy Association’s drug development program, which is exclusively focused on funding the discovery and clinical
application of treatments and cures for neuromuscular diseases. MVP funds projects from proof-of-principle studies through phase 2 trials. For-profit entities are required to contribute funds that match or exceed MDA’s contribution. MDA will negotiate return
on investment. Projects funded by MVP are milestone-driven projects, with funds released according to the completion of pre-agreed upon sections of the project.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due December 1, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: November 13.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-054.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7d9lPllA$" target="_blank"><span style="color:#0563C1">Cancer Intervention and Surveillance Modeling Network (CISNET) (U01
Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) is a continuation of Cancer Intervention and Surveillance Modeling Network (CISNET –
<a href="https://urldefense.com/v3/__https://cisnet.cancer.gov__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH77RGrx9E$"><span style="color:#0563C1">https://cisnet.cancer.gov</span></a>) program. This FOA invites multiple PD/PI applications for collaborative research projects using simulation and other modeling techniques for specific cancer
types. The proposed research is expected to generate sophisticated, evidence-based decision tools that could inform international/national/regional/local decisions on the most efficient utilization of existing and emerging technologies and strategies for the
control of cancer.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 10, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: November 28.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-386.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7rz24jcA$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-385.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7NO38deU$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these funding opportunity announcements (FOAs) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning
to increase risk for psychiatric disorders with onset in late childhood, adolescence, or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add
new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should
address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated
that knowledge gained from the research supported by these FOAs will inform the development of improved intervention, prevention and/or therapeutic strategies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 10, 2019; November 16, 2020; and November 16, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for December 2019 deadline: November 28.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-20-001.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7K_rmzL0$" target="_blank"><span style="color:#0563C1">Strategies to Improve Health Outcomes and to Reduce Disparities in
Rural Populations (R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This RFA encourages research to promote a greater understanding of the challenges faced by rural population groups, for the development (or adoption/adaptation) of evidence-based interventions
that can reduce health risks faced by rural Americans. Both prevention and treatment interventions are needed to address rural health issues. Prevention strategies should address and measure reductions in risk factors and enhancement of protective factors,
while treatment approaches would seek to measure and address amelioration of health in individuals living with existing conditions. To accomplish these goals, the research community will be encouraged to use a wide range of culturally appropriate methodological
approaches that can enhance access to and acceptability of interventions in rural settings, such as telehealth and community-based prevention research, where appropriate. It is our hope that research supported under this RFA will contribute to our knowledge
of the sustainability of health promotion and disease prevention strategies in rural settings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 13, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: November 30.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.afar.org/research/funding/afar-research-grants/__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Wz9YpxQ$" target="_blank"><span style="color:#0563C1">American Federation for Aging Research: Research Grants for Junior Faculty</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The major goal of this program is to assist in the development of the careers of junior investigators committed to pursuing careers in the field of aging research. GMRF and AFAR support
research projects concerned with understanding the<b> basic mechanisms of aging </b>rather than disease-specific research. Projects investigating age-related diseases are supported if approached from the point of view of how basic aging processes may lead
to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders are also encouraged, as long as these include connections to
<b>fundamental problems in the biology of aging</b>. Projects that deal strictly with clinical problems such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Examples of potentially fundable areas of research include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Aging and immune function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Stem cell aging<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Genetic control of longevity<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Neurobiology and neuropathology of aging<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Invertebrate or vertebrate animal models<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Cardiovascular aging<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Aging and cellular stress response<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Metabolic and endocrine changes<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due December 16, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: December 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.afar.org/research/funding/big/__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7wlRrz0Y$" target="_blank"><span style="color:#0563C1">Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Sponsored by the Glenn Foundation for Medical Research, in collaboration with the American Federation for Aging Research (AFAR), the “Breakthroughs in Gerontology (BIG)” initiative provides
timely support to a small number of research projects that are relatively high risk but which offer significant promise of yielding transforming discoveries in the fundamental biology of aging. Projects which build on early discoveries that show translational
potential for clinically-relevant strategies, treatments and therapeutics, addressing human aging and health span are also considered. Projects that focus on specific diseases or on assessment of health care strategies will receive lower priority, unless the
research plan makes clear and direct connections to fundamental issues in the biology of aging and/or on the translational aspects of basic discovery to human aging and healthspan. Two three-year awards will be made in 2020, at the level of $300,000 total
($100,000 per year), of which a maximum of 8% may be used for indirect expenses or institutional overhead. The amount and the duration of the award may be modified if during the review process or at the funding stage it is evident that such modifications would
better serve the objectives of the program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due December 16, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: December 4.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-009.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Tq7lnYc$" target="_blank"><span style="color:#0563C1">Continuation of the Consortium for the Study of Chronic Pancreatitis,
Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) to conduct
and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC
is composed of several Clinical Centers (CCs) and one Coordination and Data Management Center (CDMC). This FOA will accept both clinical studies and clinical trials that contribute to the research objectives of the CPDPC. The Consortium, since its establishment
in Fall 2015, has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis
and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. To effectively contribute
to the ongoing CPDPC clinical studies, each CC application should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see
<a href="https://urldefense.com/v3/__https://cpdpc.mdanderson.org/clinicalstudies.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7wZJ6dgU$" title="Link to Non-U.S. Government Site">
<span style="color:#0563C1">https://cpdpc.mdanderson.org/clinicalstudies.html</span></a>). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise
and technological capabilities present in all of the CCs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 17, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: December 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-aa-20-003.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH78PqE7ZA$" target="_blank"><span style="color:#0563C1">Consortium on the Neurobiology of Adolescent Drinking in Adulthood
(NADIA) Research Projects (Collaborative U01 – Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits research cooperative agreements as part of the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium to elucidate persistent
changes in complex brain function-behavior relationships following adolescent alcohol exposure. The purpose of this FOA is to support collaborative research projects (U01) focusing on research efforts across different research institutions investigating the
consequences of repeated adolescent alcohol exposure on brain maturation and adult abilities. Since NIAAA is interested in supporting experimental studies on the effects of controlled alcohol doses and exposure periods, this initiative is limited to
<b>animal studies only</b>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 18, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: December 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://mchb.hrsa.gov/fundingopportunities/Default.aspx?id=af14b725-64b3-4b52-a7bd-716e93c23707__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Ja7evv8$"><span style="color:#0563C1">R40 Maternal and Child Health Secondary Data Analysis
Research (MCH SDAR) Program</span></a><b><br>
</b>The R40 MCH SDAR Program supports applied MCH research that exclusively utilizes the secondary analyses of existing publicly available and accessible national databases and/or administrative records to improve the health and well-being of MCH populations.
The program accelerates the pace of research in a cost-effective way by providing researchers with an opportunity to pose new research questions, test new hypotheses, and determine pathways and feasibility of interventions using existing data sets, rather
than conducting primary data collection, which is both costly and time-consuming. Findings from the research supported by the R40 MCH SDAR Program are expected to:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Strengthen and expand topics addressed by the Title V MCH Services Block Grant National Performance Domains (see Appendix C). For more background materials
on the Title V Program, see: <a href="https://urldefense.com/v3/__http://mchb.hrsa.gov/programs/titlevgrants/index.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7gCZ2_aQ$">
<span style="color:#0563C1">http://mchb.hrsa.gov/programs/titlevgrants/index.html</span></a>. By supporting research on MCH populations, the R40 MCH SDAR Program aims to inform HRSA Maternal and Child Health Bureau’s (MCHB’s) other investments and programs,
see: <a href="https://urldefense.com/v3/__https://mchb.hrsa.gov/maternal-child-health-initiatives__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Gn7N524$"><span style="color:#0563C1">https://mchb.hrsa.gov/maternal-child-health-initiatives</span></a>;
<b><o:p></o:p></b></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Address HRSA MCHB’s Strategic Research Issues (see Appendix A) such as improving public health systems and infrastructure, reducing health inequalities,
increasing quality of and access to care, and/or promoting the health of MCH populations;
<b><o:p></o:p></b></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Address Healthy People 2020 objectives that are relevant to the proposal. Proposals should connect the proposed topic with the Healthy People 2020 objectives;<b><o:p></o:p></b></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Address HRSA’s clinical priorities, namely, opioid use disorder, mental health, telehealth, childhood obesity, and maternal mortality. Study findings will
further develop the evidence base for the above clinical priority topics; and <b>
<o:p></o:p></b></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Address emerging research topics of regional and national significance that highlight new data, knowledge, evidence, and strategies for addressing the
burden of diseases that affect MCH populations.<b><o:p></o:p></b></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">HRSA expects each R40 MCH SDAR award recipient to complete the following major activities:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Conduct applied or translational research on critical and emerging MCH issues through appropriate secondary analyses of existing national databases and/or
administrative records that are aligned with research goals; <b><o:p></o:p></b></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Develop and submit a dissemination plan for the distribution of research findings and products to scientific, professional, and lay audiences.<b>
<o:p></o:p></b></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 8, 2020.<span style="color:red"> Med-RA deadline to receive draft documents: January 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2019/nsf19612/nsf19612.htm?WT.mc_id=USNSF_25&WT.mc_ev=click__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7gVY_oWQ$" target="_blank"><span style="color:#0563C1">NSF Law & Science</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Law & Science Program considers proposals that address social scientific studies of law and law-like systems of rules, as well as studies of how science and technology are applied
in legal contexts. The Program is inherently interdisciplinary and multi-methodological. Successful proposals describe research that advances scientific theory and understanding of the connections between human behavior and law, legal institutions, or legal
processes; or the interactions of law and basic sciences, including biology, computer and information sciences, STEM education, engineering, geosciences, and math and physical sciences. Scientific studies of law often approach law as dynamic, interacting with
multiple arenas, and with the participation of multiple actors. Fields of study include many disciplines, and often address problems including, though not limited, to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Crime, Violence, and Policing<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Cyberspace<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Economic Issues<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Environmental Science<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Evidentiary Issues<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Forensic Science<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Governance and Courts<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Human Rights and Comparative Law<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Information Technology<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Legal and Ethical Issues related to Science<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Legal Decision Making<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Legal Mobilization and Conceptions of Justice<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Litigation and the Legal Profession<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Punishment and Corrections<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Regulation and Facilitation of Biotechnology (e.g., Gene Editing, Gene Testing, Synthetic Biology) and Other Emerging Sciences and Technologies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Use of Science in the Legal Processes<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 15, 2020 and August 3, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for January 2020 deadline: January 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-064.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7PSCc-pM$" target="_blank"><span style="color:#0563C1">Improving the Reach and Quality of Cancer Care in Rural Populations
(R01 Clinical Trial Required)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations.
The FOA encourages two types of applications: (1) observational research that includes intervention pilot testing to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or (2) intervention
research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. The focus for observational studies with pilot testing is understanding and addressing the predictive and/or mediating role of social
determinants of health, barriers to care, and treatment. The focus for intervention research is addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation
and dissemination in low-income rural areas, so applications should seek to develop, adapt, implement, and test interventions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 15, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-367.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7O0cLGNU$" target="_blank"><span style="color:#0563C1">Maximizing Investigators’ Research Award (R35 – Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is
to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach
problems more creatively;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound
to specific aims proposed in advance of the studies;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances
for important breakthroughs;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 17, 2020; May 18, 2020; January 19, 2021; May 17, 2021; January 18, 2022; and May 17, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for January 2020 deadline: January 6.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Low Cost Detection of Cognitive Decline in Clinical Settings (R61 / R33 / R01Clinical Trial Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-050.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7Q_-WxyE$" target="_blank"><span style="color:#0563C1">R61 / R33</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications to pursue development and validation studies of cognitive screening instruments or assessments in clinical settings and
to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA will support an R61 pilot phase
(Stage I) which will allow researchers to develop and validate tools for cognitive assessment and then create scalable, tailored interventions for patients experiencing cognitive decline to help overcome barriers to uptake. If successful, researchers may transition
to an R33 phase (Stage IV) for implementation of pragmatic trials. All applicants are required to address health disparities. This FOA does not require preliminary data.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-051.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7s0QmRUI$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications to pursue validation studies of cognitive screening instruments or assessments in clinical settings and to translate these
screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA requires prior preliminary data gathered during
the development of cognitive screening tools and/or assessments. This FOA will also support research to validate these tools as well as their implementation in large clinical settings. Plans for validation of cognitive impairment against relevant Alzheimer’s
disease and Alzheimer’s disease-related dementias (AD/ADRD) biomarkers are encouraged but not required<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 16.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Dementia Care: Home- and Community-Based Services (HCBS) (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ag-20-038.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH79-4B4zA$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-037.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7m_ztCoA$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications seeking to examine the outcomes of care for persons with Alzheimer's disease and Alzheimer's disease-related dementias
(AD/ADRD) by identifying home- and community-based services (HCBS) used, as well as barriers to accessing these types of care and unmet needs of persons with AD/ADRD concerning care and services.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 3, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-033.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7anAS3Lk$" target="_blank"><span style="color:#0563C1">NIA Behavioral and Social Research Leaders in Alzheimer’s Disease
and Its Related Dementias (NIA BSR LEADR) (DP1 - Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIA Behavioral and Social Research Leaders in Alzheimer’s Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose
to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer’s disease and Alzheimer’s disease-related
dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from individuals with diverse backgrounds. NIA encourages applications on a variety of AD/ADRD topics in which behavioral and social research can contribute, such as
dementia care, dementia caregiver research, cognitive and dementia epidemiology, behavioral and social pathways of AD/ADRD, early psychological changes preceding AD/ADRD, prevention of AD/ADRD, and disparities in AD/ADRD or dementia-related outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Responsive applications must reflect a new insight into a potential solution to an important problem related to AD/ADRD that can be addressed with exceptionally innovative or unconventional
behavioral and/or social science methods. This initiative is to support investigators who intend to pursue new research directions distinct from those they currently or previously conducted. While the proposed research may have the investigator’s prior work
and expertise as its foundation, it cannot be a minor extension or scale-up of a current or past research enterprise.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 3, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 21.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-027.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7kKj5Eew$" target="_blank"><span style="color:#0563C1">Innovations to Foster Healthy Longevity in Low-Income Settings (R03
Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications for research and development to improve functioning and quality of life for the elderly, especially the disabled elderly,
living in low- and middle-income countries (LMICs), or to improve functioning and quality of life for low-income, disabled, and isolated elderly living in high-income countries. Applications may address the needs of the elderly directly or indirectly by supporting
family or other informal caregivers and service providers. Applications likely to have an impact on a large scale are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 3, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-001.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7gbQ3MNo$" target="_blank"><span style="color:#0563C1">Ethical Issues in Translational Science Research (R01 Clinical Trial
Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support research to address ethical issues in translational science research. Collaboration between bioethicists, legal scholars,
social scientists, and translational research scientists is encouraged. The focus is to develop knowledge to inform the ethical development, modification, or application of novel findings, technologies, and approaches to improve human health, including their
impact on individuals, families, communities, and society.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 6, 2020; October 6, 2020; and October 6, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for February 2020 deadline: January 27.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 and Single-site U01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-027.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7EM9injQ$" target="_blank"><span style="color:#0563C1">Collaborative U01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-026.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7LbNyT5I$" target="_blank"><span style="color:#0563C1">Single-site U01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements seek applications proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non European ancestry to advance
the important goal of global mental health discovery and equity. These FOAs are two of several supporting the “Ending Disparities in Mental Health” (<a href="https://urldefense.com/v3/__https://www.nimh.nih.gov/about/organization/gmh/ending-disparities-in-mental-health-edify-mh.shtml__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7rnsnoCE$"><span style="color:#0563C1">EDIfy-MH</span></a>)
program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 14 , 2020; September 15, 2020; September 15, 2021; and September 15, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for February 2020 deadline: February 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-022.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7E_Kmhjg$" target="_blank"><span style="color:#0563C1">Enabling Technologies and Transformative Platforms for HLBS Research
(R33 – Clinical Trials Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic
and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated
with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of
early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where
the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 9, 2020; July 9, 2020; March 9, 2021; and July 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for March 2020 deadline: February 25.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-035.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7oVktpCA$" target="_blank"><span style="color:#0563C1">Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical
Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the
National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors,
and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals,
human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during
the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 17, 2020; July 17, 2020; November 17, 2020; March 17, 2021; July 19, 2021; November 17, 2021; March 17, 2022; July 19, 2022; and November 7, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for March 2020 deadline: March 4.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed / R01 Basic Experimental Studies
with Humans Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-373.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7UC0SrEc$" target="_blank"><span style="color:#0563C1">R01 Clinical Trials Not Allowed</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors
affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA’s companion for
basic experimental studies with humans (below).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-384.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7HX4R6fA$" target="_blank"><span style="color:#0563C1">R01 Basic Experimental Studies with Humans Required</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these
factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables)
and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as “prospective basic science studies involving human participants”
that meet the NIH definition of basic research and fall within the NIH definition of a clinical trials (see, e.g.,
<a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-024.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7JlW5y68$"><span style="color:#0563C1">NOT-OD-19-024</span></a>) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions
(i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 17, 2020 and March 17, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for March 2020 deadline: March 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-065.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7U3ZiLdg$" target="_blank"><span style="color:#0563C1">Understanding Phage Biology to Support the Development of Bacteriophage
Therapy (R21 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This initiative will support basic and translational research to address knowledge gaps that hinder the development and regulation of bacteriophage used to prevent and treat drug-resistant
bacterial infections.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 18, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: March 5.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Patient Activation for Self-Management of Chronic Conditions (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-382.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7p2w1ihA$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-381.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH79vstmKE$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 5, 2020; February 5, 2021; June 5, 2021; February 5, 2022; June 5, 2022; and February 5, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 2020 deadline: May 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Basic Science (R03 Clinical Trials Not Allowed); Archiving and Leveraging Existing Data Sets
for Analyses (R03 Clinical Trial Not Allowed); Systems Biology (R03 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-19-392.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7yBDAP-o$" target="_blank"><span style="color:#0563C1">Basic Science R03</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer’s disease
and Alzheimer’s disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in
the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative
AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-19-391.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7w_qYGRY$" target="_blank"><span style="color:#0563C1">Archiving and Leveraging Existing Data Sets for Analyses R03</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This R03 will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer’s
disease and Alzheimer’s disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to
encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies
developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-19-393.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7eMmbAAI$" target="_blank"><span style="color:#0563C1">Systems Biology R03</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This R03 will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals
with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD,
and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals
from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires November 17, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-034.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH75AJPLM0$" target="_blank"><span style="color:#0563C1">Fundamental Mechanisms of Affective and Decisional Processes in Cancer
Control (R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have
key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control
researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and
decision sciences with downstream implications for cancer prevention and control.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2020 standard date: January 23.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Perception and Cognition Research to Inform Cancer Image Interpretation (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-389.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7XMopO9M$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-387.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7OWB3BaI$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology
and pathology, in order to improve the accuracy of cancer detection and diagnosis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2020 R01 standard date: January 23; Med-RA deadline to receive draft documents for February 16, 2020 R21 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-369.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH758pDXfs$" target="_blank"><span style="color:#0563C1">Development of Animal Models and Related Biological Materials for Research
(R21 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand
human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs)
to align with the <a href="https://urldefense.com/v3/__https://orip.nih.gov/__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7I3kODwM$"><span style="color:#0563C1">Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission</span></a>. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple
body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not acceptable to this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-375.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7PkmMXLw$" target="_blank"><span style="color:#0563C1">Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric
Research Data (R03 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and
phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated
genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research
and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets
generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-377.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7fRo6nvY$" target="_blank"><span style="color:#0563C1">Omics-guided Biobehavioral Interventions for Improved Health Outcomes:
A Step Forward in Translation (R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics,
microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2020 standard date: January 23.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-374.html__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7pJDlOmI$" target="_blank"><span style="color:#0563C1">Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical
Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging.
Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 26, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for January 25, 2020 standard date: January 13.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20505/nsf20505.htm__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7i1WTKzQ$" target="_blank"><span style="color:#0563C1">Transitions to Excellence in Molecular and Cellular Biosciences Research (Transitions)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Division of Molecular and Cellular Biosciences (MCB) has developed a new opportunity to enable researchers with a strong track record of prior accomplishment to pursue a new avenue
of research or inquiry. This funding mechanism is designed to facilitate and promote a PI’s ability to effectively adopt empowering technologies that might not be readily accessible in the PI’s current research environment or collaboration network. Transformative
research likely spans disciplines and minimizing the practical barriers to doing so will strengthen research programs poised to make significant contributions. The award is intended to allow mid-career or later-stage researchers (Associate or Full Professor,
or equivalent) to expand or make a transition in their research programs via a sabbatical leave or similar mechanism of professional development and then develop that research program in their own lab. This award will also enable the PI to acquire new scientific
or technical expertise, facilitate the investigator’s competitiveness, and potentially lead to transformational impacts in molecular and cellular bioscience. The award would fund up to six months of PI salary during the first sabbatical or professional development
year, followed by support for continued research for two subsequent years upon the PI’s return to normal academic duties. Through this solicitation MCB and NSF hope to develop a novel mechanism that will encourage investigators to expand and/or transition
to new research areas aligned with MCB priorities, to increase retention of investigators in science, and to ensure a diverse scientific workforce that remains engaged in active research. Highest funding priority is given to proposals that have outstanding
intellectual merit and broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. Proposals should also demonstrate a strong record of prior accomplishment,
a compelling plan for professional development that will enable the PI to forge a new direction in their scholarship, and a strong rationale for why this support is needed for the PI to become competitive in the new research area. Support for the proposed
transition from the PI’s department, described in a letter from the department chair or equivalent, will also be required. Proposals that do not describe a plan for a transition in research direction will be considered unresponsive. Proposals that are motivated
to understand the molecular and cellular basis of disease and disease treatments are not appropriate for the Division and will be returned without review. Proposals addressing major open questions at the intersections of biology with other disciplines, such
as physics, chemistry, mathematics, computer sciences, and engineering are of particular interest to the program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals accepted anytime.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Forecasts<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=320901__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7LmZQcNY$"><span style="color:#0563C1">Community-wide Approaches for Healthy Children</span></a><b><br>
Department of Health and Human Services<br>
Office of the Assistant Secretary for Health<o:p></o:p></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date:
</span></b><span style="font-size:12.0pt;font-family:Palatino">December 6, 2019<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated due date:
</span></b><span style="font-size:12.0pt;font-family:Palatino">March 6, 2020<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Office of Minority Health (OMH) is offering a funding opportunity to assess the effectiveness of interventions targeted community-wide in order to prevent adverse childhood experiences
(ACEs) in racial/ethnic minority and disadvantaged populations. Funding will be used to implement and evaluate prevention approaches that expand or improve upon evidence-based interventions or promising research evidence. OMH will fund awards annually for
a project period of up to 2 years. A limited competition among grant recipients making satisfactory progress will be considered for a third year of funding. This funding opportunity builds upon lessons learned from other interventions targeted specifically
toward individual youth who have experienced trauma and aligns with an enhanced Departmental focus on primary prevention of ACEs. BACKGROUND: ACEs disproportionately impact racial/ethnic minority children and are linked to negative, lasting outcomes for health
and wellbeing and higher health care costs. The effects of ACEs include poor physical health, chronic disease, substance use and mental health issues, unemployment and poverty. ACEs are often associated with a wide range of experiences (e.g. food insecurity,
housing insecurity, poverty, community violence), and prevention of ACEs requires community-level responses. <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=320917__;!5Xm4_O-4tfk!mR_X7Bjr5p4F-DjZ_PRiXoTyvaOO1ZTFISjlUzPeLb_ZYGQWU2m6vlVrezN_SA2JR6pPYmYjwAH7TFahrKk$"><span style="color:#0563C1">State/Tribal/Territorial Partnership Initiative to Document, Sustain and Spread
Disparity-Reducing Interventions</span></a><b><br>
Department of Health and Human Services<br>
Office of the Assistant Secretary for Health<o:p></o:p></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated post date:
</span></b><span style="font-size:12.0pt;font-family:Palatino">December 6, 2019<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Estimated due date:
</span></b><span style="font-size:12.0pt;font-family:Palatino">March 6, 2020<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The State/Tribal/Territorial Partnership Initiative is a demonstration cooperative agreement to identify best practices for documenting, sustaining and spreading health disparity-reducing
interventions in racial and ethnic minority populations to ultimately improve health outcomes. Ultimately, this award is intended to enhance the capacity of state/tribal/territorial government agencies to: (1) Implement a public health quality improvement
model that can be applied to any racial or ethnic health disparity area; and (2) Develop needed partnerships to sustain successful interventions after the award period. BACKGROUND INFORMATION: State, tribal and territorial government agencies are uniquely
positioned to lead efforts for identifying, sustaining and spreading health disparity-reducing interventions using a public health quality improvement model that can be applied to any preventive or clinical issue. For the State/Tribal/Territorial Partnership
Initiative, each awardee will be expected to: (1) Utilize baseline data to produce a health disparities profile on 1 to 2 topics aligned with the Department of Health and Human Services’ priority areas (e.g., opioid epidemic, HIV, sickle cell disease, physical
activity, hepatitis B and maternal mortality), including the incorporation of any relevant Healthy People 2020 leading health indicator; (2) Implement an evidence-based intervention and/or promising practice in the geographical hotspot(s) consistent with the
baseline data; and (3) Create a manuscript of the results and impact of the project, including the awardee’s identified best practices for sustaining and spreading successful interventions. Awardees will be expected to partner with state/tribal/territorial
government agencies and additional health and/or community-based agencies/organizations. The Office of Minority Health will work closely with awardees, and technical assistance will be available for community partnership development and data collection activities
to support the success of projects. <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>